Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

<p>Abstract</p> <p>Background</p> <p>Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the lo...

Full description

Bibliographic Details
Main Authors: Danese Saverio, Nardi Mario, Cartenì Giacomo, Manzione Luigi, Vernaglia Lombardi Alessandra, Marinaccio Marco, Febbraro Antonio, Colucci Giuseppe, Di Vagno Giovanni, Scambia Giovanni, Biamonte Rosalbino, De Placido Sabino, Pignata Sandro, Valerio Maria, de Matteis Andrea, Massidda Bruno, Gasparini Giampietro, Di Maio Massimo, Pisano Carmela, Perrone Francesco
Format: Article
Language:English
Published: BMC 2006-01-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/6/5

Internet

http://www.biomedcentral.com/1471-2407/6/5

Similar Items